The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women

Baber RJ Panay N and the IMS Writing Group (2016) 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric 19(2): 109–150.

Hamoda H Panay N Arya R and Savvas M (2016) The British Menopause Society & Women’s Health Concern 2016 recommendations on hormone replacement therapy in menopausal women. Post Reproductive Health 22(4): 165–183.

Manson JE Chlebowski RT Stefanick ML , et al. (2013) Menopausal hormone therapy and health outcomes during the intervention and extended post stopping phases of the Women’s Health Initiative randomized trials. JAMA : The Journal of the American Medical Association 310: 1353–1368.

National Institute for Health and Care Excellence. Menopause: clinical guideline – methods, evidence and recommendations, (NG23), 12 November, Version 1.5. Available at: https://www.nice.org.uk/guidance/ng23/evidence/fullguideline-559549261 (accessed 1st July 2020).

Avis NE Carolina N and Crawford SL ( 2015) Duration of menopausal vasomotor symptoms over the menopause transition. JAMA : The Journal of the American Medical Association 175(4), 531–539.

Baber RJ Panay N and the IMS Writing Group (2016) 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric 19(2): 109–150.

Constantine GD Revicki DA Kagan R , et al. (2019) Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms. Menopause 26(5): 513–519.

MacLennan AH Broadbent JL Lester S , et al. (2004) Oral estrogen and combined estrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews 4: CD002978.

National Institute for Health and Care Excellence (2015) Menopause: diagnosis and management of menopause (NICE guideline 23). Available at: https://www.nice.org.uk/guidance/ng23

Sarri G Pedder H Dias S , et al. (2017) Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG: An International Journal of Obstetrics and Gynaecology 124(10): 1514–1523.

Georgakis MK Thomopoulos TP Diamantaras AA , et al. (2016) Association of age at menopause and duration of reproductive period with depression after menopause: a systematic review and meta-analysis. JAMA Psychiatry 73(2): 139–149.

Gleason CE Dowling NM Wharton W , et al. (2015) Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-Cognitive and Affective Study. PLoS Medicine 12: e1001833–e1001833.

Gordon JL Rubinow DR Eisenlohr-Moul TA , et al. (2018) Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry 75: 149–157.

Maki PM Freeman EW Greendale GA , et al. (2010) Summary of the National Institute on Aging-sponsored conference on depressive symptoms and cognitive complaints in the menopausal transition. Menopause 17: 815–822.

Mann E Smith MJ Hellier J , et al. (2012) Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncology 13: 309–318.

Rocca W Bower J Maraganore DM , et al. (2007) Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69: 1074–1083.

Studd J and Nappi RE ( 2012) Reproductive depression. Gynecological Endocrinology 28(Suppl 1): 42–45.

Studd JWW ( 2011) A guide to the treatment of depression in women by estrogens. Climacteric 14: 637–642.

Archer DF Kimble TD Lin FDY , et al. (2018) A randomized, multicenter, double-blind, study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with vaginal dryness as the most bothersome symptom. Journal of Women’s Health 27: 231–237.

Archer DF Simon JA Portman DJ , et al. (2019) Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause. Expert Review of Endocrinology & Metabolism 14(5): 301–314.

Cardozo L Lose G McClish D , et al. (2001) A systematic review of estrogens for recurrent urinary tract infections: third report of the Hormones and Urogenital Therapy Committee. International Urogynecology Journal and Pelvic Floor Dysfunction 12: 15–20.

Cody JD Richardson K Moehrer B , et al. (2009) Estrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database of Systematic Reviews 4: CD001405.

Crean-Tate KK Faubion SS Pederson HJ , et al. (2020) Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. American Journal of Obstetrics and Gynecology 222(2): 103–113.

Cruz VL Steiner ML Pompei LM , et al. (2018) Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO₂ laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause 25: 21–28.

Di Donato V Schiavi MC Iacobelli V , et al. (2019) Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part I: evaluation of efficacy. Maturitas 121: 86–92.

Labrie F Archer DF Koltun W , et al. (2018) Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 25: 1339–1353.

Labrie F Martel C Bérubé R , et al. (2013) Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. The Journal of Steroid Biochemistry and Molecular Biology 138: 359–367.

Pitsouni E Grigoriadis T Falagas ME , et al. (2017) Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas 103: 78–88.

Portman DJ Gass MLS Kingsberg S , et al. (2014) Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and The North American menopause society. The Journal of Sexual Medicine 11(12): 2865–2872.

Portman DJ Labrie F Archer DF , et al. (2015) Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause 22: 1289–1295.

Robinson D Toozs-Hobson P and Cardozo L (2013) The effect of hormones on the lower urinary tract. Menopause International 19:155–162.

Sturdee DW and Panay N ; on behalf of the IMS Writing Group (2010) Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13: 509–522.

• Suckling J Kennedy R Lethaby A , et al. Local estrogen therapy for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006 Oct 18; (4): CD001500. DOI: 10.1002/14651858.CD001500.pub2. Update in: Cochrane Database Syst Rev. 2016;8:CD001500. PMID: 17054136.

Calleja-Agius J and Brincat MP ( 2009) Effects of hormone replacement therapy on connective tissue: why is this important? Best Practice & Research Clinical Obstetrics & Gynaecology 23: 121.

Calleja-Agius J Muscat-Baron Y and Brincat MP ( 2009) Estrogens and the intervertebral disc. Menopause International 15: 127–130.

Cruz-Jentoft AJ Baeyens JP Bauer JM , et al. (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39(4): 412–423.

Greising SM Baltgalvis KA Lowe DA , et al. (2009) Hormone therapy and skeletal muscle strength: a meta-analysis. The Journal of Gerontology. Series A, Biological Sciences and Medical Sciences 64: 1071–1081.

Javed AA Mayhew AJ Shea AK , et al. (2019) Association between hormone therapy and muscle mass in postmenopausal women: a systematic review and meta-analysis. JAMA Network Open 2(8): e1910154.

Liu CJ and Latham NK (2009) Progressive resistance strength training for improving physical function in older adults. Cochrane Database of Systematic Reviews (3); article no.: CD002759.

Rizzoli R Stevenson JC Bauer JM , et al. (2014) The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas 79; 122–132.

Watt FE (2018) Musculoskeletal pain and menopause. Post Reproductive Health 24(1): 34–43. https://doi.org/10.1177/2053369118757537

• Advisory Board of the National Osteoporosis Guideline Group (2016) Archives of Osteoporosis 11(1): 25.

Bagger YZ Tanko LB Alexandersen P , et al. (2004) Two to three years of hormone replacement therapy in healthy women have long-term prevention effects on bone mass and osteoporotic fractures: the PERF study. Bone 34: 728–731.

Black DM Cummings SR Karpf DB , et al. (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535–1541.

Cauley JA Robbins J Chen Z , et al. (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA: The Journal of the American Medical Association 290: 1729–1738.

Compston J Cooper A Cooper C , et al.; on behalf of the National Osteoporosis Guideline Group (NOGG) (2014) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK. National Osteoporosis Guideline Group (NOGG). March.

Gartlehner G Patel SV Feltner C , et al. (2017) Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US Preventive Services Task Force. JAMA : The Journal of the American Medical Association 318: 2234–2249.

Kanis JA Harvey NC Cooper C , et al. A systematic review of intervention thresholds based on FRAX. A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Khosla S Burr D Caulley J , et al. (2007) Bisphosphonate associated osteonecrosis of the jaw: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 22: 1479–1491.

Lindsay R Gallagher JC Kleerekoper M , et al. (2005) Bone response to treatment with lower dosages of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporosis International 4: 372–379.

Mortensen SJ Mohamadi A Wright CL , et al. (2020) Medications as a risk factor for fragility hip fractures: a systematic review and meta-analysis. Calcified Tissue International 107(1): 1–9. DOI: 10.1007/s00223-020-00688-1. Epub 2020 Apr 7. PMID: 32253446.107(1): 1–9. doi: 10.1007/s00223-020-00688-1. Epub 2020 Apr 7. PMID: 32253446.

Shane E Burr D Abrahamsen B , et al. (2014) Atypical subtrochanteric and diaphyseal femoral fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 29: 1–23.

Stevenson JC ; International Consensus Group on HRT and Regulatory Issues (2006) HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes? Human Reproduction 21: 1668–1671.

The FRAX® WHO fracture risk assessment tool. Available at: www.shef.ac.uk/FRAX (accessed August 2016).

Zhu L Jiang X Sun Y , et al. (2016) Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause 23(4): 461–470.

Boardman HM Hartley L Eisinga A , et al. (2015) Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews 3: CD002229.

Crandall CJ Hovey KM Andrews C , et al. (2017) Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women’s Health Initiative Observational Study. Menopause 24: 1145–1153.

Crandall CJ Hovey KM Andrews CA , et al. (2018) Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause 25: 11–20.

Collins P Webb CM de Villiers TJ , et al. (2016) Cardiovascular risk assessment in women – an update. Climacteric 19(4): 329–336.

Grodstein F Manson JE and Stampfer MJ (2006) Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. Journal of Women’s Health 15: 35–44.

Harman SM Black DM Naftolin F , et al. (2014) Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Annals of Internal Medicine 161: 249–260.

Hodis HN Mack WJ Henderson VW , et al.; ELITE Research Group (2016) Vascular effects of early versus late postmenopausal treatment with estradiol. The New England Journal of Medicine 374(13): 1221–1231.

Hsia J Langer RD Manson JE , et al. (2006) Conjugated equine estrogens and coronary heart disease: the Women’s Health Initiative. Archives of Internal Medicine 166: 357–365.

Manson JE Aragaki AK Bassuk SS , et al.; WHI Investigators (2019) Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy: a randomized trial. Annals of Internal Medicine. Epub ahead of print 2019. DOI: 10.7326/M19-0274

Manson JE Aragaki AK Rossouw JE , et al.; WHI Investigators (2017) Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative Randomized Trials. JAMA: The Journal of the American Medical Association 318(10): 927–938.

Manson JE Chlebowski RT Stefanick ML , et al. (2013) Menopausal hormone therapy and health outcomes during the intervention and extended post stopping phases of the Women’s Health Initiative randomized trials. JAMA : The Journal of the American Medical Association 310: 1353–1368.

Mikkola TS Tuomikoski P Lyytinen H , et al. (2015a) Increased cardio-vascular mortality risk in women discontinuing postmenopausal hormone therapy. The Journal of Clinical Endocrinology and Metabolism 100(12): 4588–4594. DOI: 10.1210/jc.2015-1864

Mikkola TS Tuomikoski P Lyytinen H , et al. (2015b) Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 22: 976–983.

Rossouw JE Prentice RL Manson JE , et al. (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA: The Journal of the American Medical Association 297: 1465–1477.

Salpeter S ( 2006) Mortality associated with hormone replacement therapy in younger and older women. Journal of General Internal Medicine: Official Journal of the Society for Research and Education in Primary Care Internal Medicine 21: 401.

Salpeter SR Cheng J Thabane L , et al. (2009) Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. The American Journal of Medicine 122(11): 1016–1022.e1.

Schierbeck LL Rejnmark L Tofteng CL , et al. (2012) Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. British Medical Journal 345: e6409.

Stevenson JC Hodis HN Pickar JH , et al. (2009) Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis 207: 336–340.

• Writing group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomised controlled trial. JAMA : The Journal of the American Medical Association 288: 321–333.

Espeland MA Shumaker SA Leng I , et al. (2013) Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Internal Medicine 173: 1429–1436.

Gleason CE Dowling NM Wharton W , et al. (2015) Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-Cognitive and Affective Study. PLoS Medicine 12: e1001833.

Kuh D Cooper R Moore A , et al. (2018) Age at menopause and lifetime cognition: findings from a British birth cohort study. Neurology 90: e1673–e1681.

Lethaby A Hogervorst E Richards M , et al. (2008) Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database of Systematic Reviews 1: CD003122.

Maki PM and Henderson VW ( 2012) Hormone therapy, dementia, and cognition: the Women’s Health Initiative 10 years on. Climacteric 15: 256–262.

Morris E and Hornberger M ; on behalf of the British Menopause Society Medical Advisory Council Medical Advisory Council, British Menopause Society. Rapid Response BMJ.

Rapp SR Espeland MA Shumaker SA , et al.

Savolainen-Peltonen H Rahkola-Soisalo P Hoti F , et al. (2019) Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case–control study British Medical Journal 364: l665.

Shumaker SA Legault C Kuller L , et al. (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA: The Journal of the American Medical Association 291: 2947–2958.

Stefanick ML Lane DS Hays J , et al. (2003) Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA : The Journal of the American Medical Association 289: 2663–2672.

Weber MT Maki PM and McDermott MP ( 2014) Cognition and mood in perimenopause: a systematic review and meta-analysis. The Journal of Steroid Biochemistry and Molecular Biology 142: 90–98.

Anderson GL Chlebowski RT Rossouw JE , et al. (2006) Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 55(2): 103–115.

British Menopause Society Consensus statement: the risks and benefits of HRT before and after a breast cancer diagnosis. Available at: https://thebms.org.uk/wp-content/uploads/_pda/2020/04/09-BMS-ConsensusStatement-Risks-and-benefits-of-HRT-before-and-after-a-breast-cancer-diagnosis-APR2020.pdf

Chlebowski RT Anderson GL , Aragaki AK , et al. (2020) Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA : The Journal of the American Medical Association 324(4): 369–380.

Cho H Ouh Y Lee JK , et al. (2019) Effects of hormone therapy on recurrence in endometrial cancer survivors: a nationwide study using the Korean Health Insurance Review and Assessment Service database. Journal of Gynecologic Oncology 30(4): e51.

Collaborative Group on Epidemiological Studies of Ovarian Cancer (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385: 1835–1842.

Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350: 1047–1059.

Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394(10204): 1159–1168.

Deli T Orosz M and Jakab A ( 2020) Hormone replacement therapy in cancer survivors – review of the literature. Pathology Oncology Research: POR 26(1): 63–78.

Fournier A Berrino F and Clavel-Chapelon F ( 2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment 107(1): 103–111.

Fournier A Mesrine S Dossus L , et al. (2014) Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Research and Treatment 145(2): 535–543.

Li D Ding CY and Qiu LH ( 2015) Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecologic Oncology 139(2): 355–362.

Liu Y Ma L Yang X , et al. (2019) Menopausal hormone replacement therapy and the risk of ovarian cancer: a meta-analysis. Frontiers in Endocrinology 10: 801.

Lyytinen HK Dyba T Ylikorkala O , et al. (2010) A case–control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. International Journal of Cancer 126: 483–489.

Marchetti C De Felice F Boccia S , et al. (2018) Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Critical Reviews in Oncology/Hematology 132: 111–115.

Million Women Study Collaborators (2003) Breast cancer and HRT in the Million Women Study. Lancet 362: 419–427.

Morch LS Lokkegaard E Andreasen AH , et al. (2012) Hormone therapy and different ovarian cancers: a national cohort study. American Journal of Epidemiology 175: 1234–1242.

Panay N ( 2012) Commentary regarding recent Million Women Study critique and subsequent publicity. Menopause International 18: 33–35.

Ravdin PM Cronin KA Howlader N , et al. (2007) The decrease in incidence of breast cancer in the United States. The New England Journal of Medicine 356: 1670–1674.

Rees M Angioli R Coleman RL , et al. (2020) European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas 134: 56–61.

Robbins AS and Clarke CA. ( 2007) Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26: 3437–3439.

Roura E Travier N Waterboer T , et al. (2016) The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: result from the EPIC cohort. PLoS One 11(1): e0147029.

Saeaib N Peeyananjarassri K Liabsuetrakul T , et al. (2020) Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database of Systematic Reviews 1: CD012559.

Sassarini J Perera M Spowart K , et al. (2018) Managing vulvovaginal atrophy after breast cancer. Post Reproductive Health 24(4): 163–165.

Shapiro S Farmer RD Mueck AO , et al. (2011a) Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 1. The collaborative reanalysis. Journal of Family Planning and Reproductive Health Care 37: 103–109.

Shapiro S Farmer RD Mueck AO , et al. (2011b) Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 2. The Women’s Health Initiative: estrogen plus progestogen. Journal of Family Planning and Reproductive Health Care 37: 165–172.

Shapiro S Farmer RD Mueck AO , et al. (2011c) Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 3. The Women’s Health Initiative: unopposed estrogen. Journal of Family Planning and Reproductive Health Care 37: 225–230.

Shapiro S Farmer RD Stevenson JC , et al. (2012) Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies Part 4: The Million Women Study. Journal of Family Planning and Reproductive Health Care 38: 102–109.

Shapiro S Farmer RD Stevenson JC , et al. (2013) Does hormone replacement therapy (HRT) cause breast cancer? An application of causal principles to three studies: Part 5. Trends in breast cancer incidence in relation to the use of HRT. Journal of Family Planning and Reproductive Health Care 39: 80–88.

Shim SH Lee SJ and Kim SN (2014) Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. European Journal of Cancer 50(9): 1628–1637.

Ulrich L ( 2014) HRT after endometrial cancer – is it safe? Maturitas 79(3): 237–238.

Vermeulen RFM Korse CM Kenter GG , et al. (2019) Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines. Climacteric 22(4): 352–360.

Yasmeen S Romano PS Pettinger M , et al. (2006) Incidence of cervical cytological abnormalities with aging in the Women’s Health Initiative: a randomized controlled trial. Obstetrics & Gynecology 108: 410–419.

Bagot CN Marsh MS Whitehead M , et al. (2010) The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. Journal of Thrombosis and Haemostasis 8(8): 1736–1744.

Canonico M Fournier A Carcaillon L , et al. (2010) Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arteriosclerosis, Thrombosis, and Vascular Biology 30: 340–345.

Canonico M Plu-Bureau G Lowe GD , et al. (2008) Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. British Medical Journal 336: 1227–1231.

Renoux C Dell'Aniello S and Suissa S ( 2010) Hormonreplacement therapy and the risk of venous thromboembolism: a population-based study. Journal of Thrombosis and Haemostasis 8: 979–986.

Scarabin PY (2018) Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis. Climacteric 4: 341–345.

Scarabin PY Oger E and Plu–Bureau G (2003) Differential association of oral and transdermal estrogen replacement therapy with venous thromboembolism risk. Lancet 362: 428–432.

Vinogradova Y Coupland C and Hippisley-Cox J (2019) Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. British Medical Journal 364: k4810.

Bagot CN Marsh MS Whitehead M , et al. (2010) The effect of estrone on thrombin generation may explain different thrombotic risk between oral and transdermal hormone replacement therapy. Journal of Thrombosis and Haemostasis 8(8): 1736–1744.

Canonico M Carcaillon L Plu-Bureau G , et al. (2016) Postmenopausal hormone therapy and risk of stroke impact of the route of estrogen administration and type of progestogen. Stroke 47: 1734–1741.

Grodstein F Manson JE Stampfer MJ , et al. (2008) Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Archives of Internal Medicine 168: 861–866.

Manson JE Chlebowski RT Stefanick ML , et al. (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA : The Journal of the American Medical Association 310: 1353–1368.

Nudy M Chinchilli VM and Foy AJ ( 2019) A systematic review and meta-regression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke. The International Journal of Cardiology 22: 123–131.

Oliver-Williams C Glisic M Shahzad , et al. (2019) The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Human Reproduction Update 25(2): 257–271.

Renoux C Dell’aniello S Garbe E , et al. (2010) Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. British Medical Journal 340: c2519.

Bidet M Bachelot A Bissauge E , et al. (2011) Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. The Journal of Clinical Endocrinology and Metabolism 96: 3864–3872.

Cartwright B Robinson J Seed PT , et al. (2016) Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomised controlled trial of the effects on bone mineral density. The Journal of Clinical Endocrinology and Metabolism 101(9); 3497–3505.

Cooper AR Baker VL Sterling EW , et al. (2011) The time is now for a new approach to primary ovarian insufficiency. Fertility and Sterility 95: 1890–1897.

Crofton PM Evans N and Bath LE (2010) Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clinical Endocrinology (Oxford) 73: 707–714.

ESHRE Guideline (2015) Management of women with premature ovarian insufficiency. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Management-of-premature-ovarian-insufficiency.aspx

Kalu E and Panay N (2008) Spontaneous premature ovarian failure: management challenges. Gynecological Endocrinology 24: 273–279.

Langrish JP Mills NL and Bath LE (2009) Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension 53: 805–811.

Maclaran K Horner E and Panay N ( 2010) Premature ovarian failure: long-term sequelae. Menopause International 16: 38–41.

Panay N and Fenton A ( 2008) Premature ovarian failure: a growing concern. Climacteric 11: 1–3.

Panay N and Fenton A ( 2012) Premature ovarian insufficiency: working towards an international database. Climacteric 15: 295–296.

Panay N and Fenton A ( 2016) Iatrogenic menopause following gynecological malignancy: time for action! Climacteric 19(1): 1–2.

Rocca WA Grossardt BR de Andrade M , et al. (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncology 7(10): 821–828.

Webber L Davies M and Anderson R (2016) ESHRE Guideline: management of women with premature ovarian insufficiency. ESHRE Guideline Group on POI. Human Reproduction 31(5): 926–937.

Canonico M Fournier A Carcaillon L , et al. (2010) Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arteriosclerosis, Thrombosis, and Vascular Biology 30: 340–345.

Canonico M Plu-Bureau G Lowe GD , et al. (2008) Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. British Medical Journal 336: 1227–1231.

Cody JD Richardson K Moehrer B , et al. (2009) Estrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database of Systematic Reviews 4: CD001405.

Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee. Committee opinion No. 532: compounded bioidentical menopausal hormone therapy. Obstet Gynecol 2012 Aug; 120(2 Pt 1): 411–5. DOI: 10.1097/AOG.0b013e318268049e. PMID: 22825109.

Espie M Daures JP Chevallier T , et al. (2007) Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecological Endocrinology: The Official Journal of the International Society of Gynecological Endocrinology 23(7): 391–397.

Fournier A Fabre A Mesrine S , et al. (2008) Use of different post-menopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26: 1260–1268.

Furness S Roberts H Marjoribanks J , et al. (2009) Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database of Systematic Reviews (2): CD000402.

Lyytinen HK Dyba T Ylikorkala O , et al. (2010) A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. International Journal of Cancer 126: 483–489.

Panay N Ylikorkala O Archer DF , et al. (2007) Ultra-low dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 10: 120–131.

Stevenson JC Durand G Kahler E , et al. (2010) Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17b-estradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas 67: 227–232.

Sturdee DW and Panay N ; on behalf of the IMS Writing Group (2010) Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13: 509–522.

Bednarek PH and Jensen JT ( 2009) Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS. International Journal of Women’s Health 1: 45–58.

Constantine GD Goldstein SR and Archer DF ( 2015) Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause 22: 36–43.

Furness S Roberts H Marjoribanks J , et al. (2009) Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database of Systematic Reviews (2): CD000402.

Lethaby A Suckling J Barlow DH , et al. (2004) Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database of Systematic Reviews 3: CD000402.

Panay N ; Medical Advisory Council of the British Menopause Society (2019 ) BMS – consensus statement: bioidentical HRT. Post Reproductive Health 25(2): 61–63.

Panay N and Studd JWW (1997) Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Human Reproduction Update 3: 159–171.

Stute P Neulen J Wildt L , et al. (2016) The impact of micronized progesterone on the endometrium: a systematic review. Climacteric 7137: 1–13.

Stute P Wildt L and Neulen J ( 2018) The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric 21(2): 111–122.

• The Writing Group for the PEPI Trial (1996) Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA: The Journal of the American Medical Association 275: 370–375.

Vinogradova Y Coupland C and Hippisley-Cox J (2019) Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the Q Research and CPRD databases. British Medical Journal 364: k4810.

Abdullahi Idle S and Hamoda H ( 2019) Outcomes of endometrial assessment in women with unscheduled bleeding on hormone replacement therapy. Post Reproductive Health 25(2): 95–99.

Burbos N Musonda P Duncan TJ , et al. (2012) Postmenopausal vaginal bleeding in women using hormone replacement therapy. Menopause International 18: 5–9.

Intercollegiate Guidelines Network (2002) Investigation of postmenopausal bleeding, a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network.

Mattson LA Ipsen HE Granqvist CJ , et al.; Study Group (2015) Ultra-low-dose estradiol and norethisterone acetate: bleeding patterns and other outcomes over 52 weeks of therapy. Climacteric 18: 419–425.

Achilli C Pundir J Ramanathan P , et al. (2017) Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertility and Sterility 107(2): 475–482.e15.

Davis SR Baber R Panay N , et al. (2019) Global Consensus Position Statement on the use of testosterone therapy for women. Climacteric 22(5): 429–434.

Elraiyah T Sonbol MB Wang Z , et al. (2014a) Clinical review: the benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. The Journal of Clinical Endocrinology and Metabolism 99(10): 3543–3550.

Elraiyah T Sonbol MB Wang Z , et al. (2014b) Clinical review: the benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. The Journal of Clinical Endocrinology and Metabolism 99(10): 3536–3542.

Fooladi E Reuter SE Bell RJ , et al. (2015) Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. Menopause 22(1): 44–49.

Heo YA ( 2019) Prasterone: a review in vulvovaginal atrophy. Drugs & Aging 36(8): 781–788.

Hirschberg AL Rodenberg C Pack S , et al.; for the APHRODITE Study Team (2008 ) Testosterone for low libido in postmenopausal women not taking estrogen. The New England Journal of Medicine 359: 2005–2017.

Islam RM Bell RJ Green S , et al. (2019) Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. The Lancet Diabetes & Endocrinology 7(10): 754–766.

Maclaran K and Panay N (2011) Managing low sexual desire in women. Women’s Health (London, England) 7: 571–581.

Maclaran K and Panay N (2012) The safety of postmenopausal testosterone therapy. Women’s Health (London, England) 8: 263–275.

Panay N Al-Azzawi F Bouchard C , et al. (2010) Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 13: 121–131.

Somboonporn W Bell RJ and Davis SR ( 2005) Testosterone for peri and postmenopausal women. Cochrane Database of Systematic Reviews 4: CD004509.

• Testosterone replacement in menopause. BMS – tools for clinicians. Available at: https://thebms.org.uk/wp-content/uploads/2020/04/08-BMS-ToolforClinician-Testosterone-replacement-in-menopause-APR2020.pdf

Wahlin-Jacobsen S Pedersen AT Kristensen E , et al. (2015) Is there a correlation between androgens and sexual desire in women? The Journal of Sexual Medicine 12: 358–373.

Atema V van Leeuwen M Oldenburg HAS , et al. (2017) An Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors: results of a pilot study. Menopause 24(7): 762–767.

Avis NE Coeytaux RR Isom S , et al. (2016) Acupuncture in Menopause (AIM) study: a pragmatic, randomized controlled trial. Menopause (New York, NY) 23: 626–637.

Bordeleau L Pritchard KI Loprinzi CL , et al. (2010) Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. Journal of Clinical Oncology 28: 5147–5152.

Chiu HY Pan CH Shyu YK , et al. (2015) Effects of acupuncture on menopause-related symptoms and quality of life in women in natural menopause: a meta-analysis of randomized controlled trials. Menopause 22(2): 234–244.

Edwards D and Panay N ( 2016) Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 19(2): 151–161.

Ee C Xue C Chondros P , et al. (2016) Acupuncture for menopausal hot flashes: a randomized trial. Annals of Internal Medicine 164(3): 146–154.

Gentry-Maharaj A Karpinskyj C Glazer C , et al. (2017) Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening. Climacteric 20(3): 240–247.

Grindler NM and Santoro NF (2015) Menopause and exercise. Menopause (12): 1351–1358.

Joffe H Guthrie KA LaCroix AZ , et al. (2014) Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Internal Medicine 174: 1058–1066.

Lambrinoudaki I Ceasu I Depypere H , et al. (2013) EMAS position statement: diet and health in midlife and beyond. Maturitas 74: 99–104.

Lethaby A Marjoribanks J Kronenberg F , et al. (2013) Phytestrogens for menopausal vasomotor symptoms. Cochrane Menstrual Disorders and Subfertility Group. Cochrane Database of Systematic Reviews 12: CD001395.

Li L Lv Y Xu L , et al. (2015) Quantitative efficacy of soy isoflavones on menopausal hot flashes. British Journal of Clinical Pharmacology 79(4): 593–604

Modi M and Dhillo WS ( 2019) Neurokinin B and neurokinin-3 receptor signaling: promising developments in the management of menopausal hot flushes. Seminars in Reproductive Medicine 37(3): 125–130.

Nelson HD Vesco KK Haney E , et al. (2006) Non-hormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA: The Journal of the American Medical Association 295: 2057–2071.

• Prague JK and Dhillo WS ( 2017) Neurokinin 3 receptor antagonism – the magic bullet for hot flushes? Climacteric 20(6): 505–509.

• Prague JK Roberts RE Comninos AN , et al. (2017) Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 389(10081): 1809–1820.

• Rees M and Panay N ( 2010) The use of alternatives to HRT for the management of menopause symptoms (updated); Opinion Paper 6. London: RCOG Scientific Advisory Committee.

Sassarini J and Lumsden MA ( 2010) Hot flushes: are there effective alternatives to estrogen? Menopause International 16: 81–88.

Simon JA Gaines T LaGuardia KD ; Extended-Release Oxybutynin Therapy for VMS Study Group (2016 ) Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. Menopause 23(11): 1214–1221.

Wei D Chen Y Wu C , et al. (2016) Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis. BJOG: An International Journal of Obstetrics and Gynaecology 123(11): 1735–1743.

Woyka J and Tanna N ( 2014) Consensus statement for non-estrogen-based treatments for menopausal symptoms. Post Reproductive Health 20(2): 76–79.

Yoon SH Lee JY Lee C , et al. (2020) Gabapentin for the treatment of hot flushes in menopause: a meta-analysis. Menopause. Epub ahead of print 10 February 2020. DOI: 10.1097/GME.0000000000001491

Baber RJ Panay N and Fenton A ; the IMS Writing Group (2016) IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 19(2): 109–150.

Collins P Webb CM de Villiers TJ , et al. (2016) Cardiovascular risk assessment in women – an update. Climacteric 19(4): 329–336.

ESHRE Guideline (2015) Management of women with premature ovarian insufficiency. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Management-of-premature-ovarian-insufficiency.aspx

Fenton A and Panay N ( 2012) The Women’s Health Initiative – a decade of progress. Climacteric 15: 205.

National Institute for Health and Care Excellence (2015) Menopause: diagnosis and management of menopause. (NICE guideline 23). Available at: https://www.nice.org.uk/guidance/ng23 (accessed 1 July 2020).

North American Menopause Society (2012) The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 19: 257–271.

Panay N ( 2013) Does hormone replacement therapy cause breast cancer? Commentary on Shapiro et al. papers, Parts 1–5. Journal of Family Planning and Reproductive Health Care 39: 72–74.

Panay N and Fenton A ( 2011) Has the time for the definitive, randomized, placebo-controlled HRT trial arrived? Climacteric 14: 195–196.

Baber R (ed.) Climacteric – The Journal of the International Menopause Society.

Management of the Menopause: The Handbook. 6th ed. 2017. London: British Menopause Society.

Morris E and Currie H (eds) Post Reproductive Health – The Journal of the British Menopause Society.

Rees M (ed.) Maturitas – The Journal of the European Menopause Society.

Singer D and Hunter M. Premature Menopause: A Multidisciplinary Approach. London: Wiley Blackwell.

Panay N Briggs P and Kovacs G (eds) (2020) Managing the menopause: 21st century solutions. In: Cambridge Medicine. 2nd ed.